Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Department of Hematology-Oncology, National University Cancer Institute, National University Hospital, Singapore.
J Clin Sleep Med. 2022 May 1;18(5):1427-1440. doi: 10.5664/jcsm.9772.
STUDY OBJECTIVES: Biological models suggest that obstructive sleep apnea (OSA) is potentially carcinogenic. We aimed to clarify the inconsistent epidemiological literature by considering various traditional and novel OSA severity indices. METHODS: We systematically searched PubMed, Embase, Scopus, and the Cochrane Library for observational or randomized studies of associations of OSA, measured by diagnostic codes or any index, each with all-cancer incidence or mortality in adults, compared with participants with no/mild OSA. Two reviewers independently selected studies, extracted data, and evaluated study bias using the Newcastle-Ottawa scale and quality of evidence using GRADE (Grading of Recommendations Assessment, Development, and Evaluation). We performed inverse variance-weighted, random-effects meta-analyses and sensitivity analyses. RESULTS: We included 20 observational studies (5,340,965 participants), all with moderate/low bias, from 1,698 records. Based on T90 (sleep duration with oxygen saturation < 90%), patients with OSA who had moderate (T90 > 1.2%, hazard ratio [HR] = 1.28, 95% confidence interval [CI] = 1.07-1.54) and severe nocturnal hypoxemia (T90 > 12%, HR = 1.43, 95% CI = 1.16-1.76) experienced 30%-40% higher pooled all-cancer risk than normoxemic patients, after multiple adjustment for covariates including obesity. Furthermore, severe nocturnal hypoxemia nearly tripled all-cancer mortality (HR = 2.66, 95% CI = 1.21-5.85). Patients with apnea-hypopnea index-defined severe OSA, but not moderate OSA, had higher all-cancer risk (HR = 1.18, 95% CI = 1.03-1.35) but similar all-cancer mortality as patients without OSA. An OSA diagnosis was not associated with all-cancer risk. Evidence quality ranged from low to moderate. Insufficient evidence was available on the oxygen desaturation index, lowest/median saturation, and arousal index. CONCLUSIONS: In patients with OSA, nocturnal hypoxemia is independently associated with all-cancer risk and mortality. Future studies should explore if risk differs by cancer type, and whether cancer screening and OSA treatment are beneficial. SYSTEMATIC REVIEW REGISTRATION: Registry: PROSPERO; URL: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=220836; Identifier: CRD42021220836. CITATION: Tan BKJ, Teo YH, Tan NKW, et al. Association of obstructive sleep apnea and nocturnal hypoxemia with all-cancer incidence and mortality: a systematic review and meta-analysis. . 2022;18(5):1427-1440.
研究目的:生物学模型表明阻塞性睡眠呼吸暂停(OSA)具有潜在致癌性。我们旨在通过考虑各种传统和新型 OSA 严重程度指标来阐明不一致的流行病学文献。
方法:我们系统地检索了 PubMed、Embase、Scopus 和 Cochrane 图书馆中关于 OSA 的观察性或随机研究,OSA 通过诊断代码或任何指标进行测量,每项研究均与无/轻度 OSA 的参与者相比,评估了 OSA 与所有癌症发病率或死亡率的相关性。两位评审员独立选择研究、提取数据,并使用纽卡斯尔-渥太华量表评估研究偏倚,使用 GRADE(推荐评估、制定与评价分级)评估证据质量。我们进行了逆方差加权、随机效应荟萃分析和敏感性分析。
结果:我们纳入了 20 项观察性研究(5340965 名参与者),均来自 1698 条记录,偏倚程度为中度/低度。基于 T90(睡眠期间氧饱和度<90%的时间),中度(T90>1.2%,风险比[HR] = 1.28,95%置信区间[CI] = 1.07-1.54)和严重夜间低氧血症(T90>12%,HR = 1.43,95% CI = 1.16-1.76)的 OSA 患者的总体癌症风险比正常氧合患者高 30%-40%,调整了包括肥胖在内的多种协变量后。此外,严重夜间低氧血症使所有癌症死亡率几乎增加了两倍(HR = 2.66,95% CI = 1.21-5.85)。患有睡眠呼吸暂停低通气指数定义的严重 OSA 的患者,而不是中度 OSA 的患者,其总体癌症风险更高(HR = 1.18,95% CI = 1.03-1.35),但与无 OSA 的患者的总体癌症死亡率相似。OSA 诊断与总体癌症风险无关。证据质量从低到中等。关于氧减指数、最低/中位数饱和度和觉醒指数的证据不足。
结论:在 OSA 患者中,夜间低氧血症与癌症风险和死亡率独立相关。未来的研究应探讨不同癌症类型的风险是否存在差异,以及癌症筛查和 OSA 治疗是否有益。
系统评价注册:PROSPERO;网址:https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=220836;标识符:CRD42021220836。
引文:Tan BKJ,Teo YH,Tan NKW,等。阻塞性睡眠呼吸暂停与夜间低氧血症与所有癌症发病率和死亡率的关系:系统评价和荟萃分析。 2022;18(5):1427-1440。
J Am Coll Cardiol. 2013-6-13
Cochrane Database Syst Rev. 2022-2-1
Ann Am Thorac Soc. 2022-3
Chin Med J (Engl). 2025-9-5
Sleep Breath. 2024-11-30
Eur Arch Otorhinolaryngol. 2024-6
Cancer Epidemiol Biomarkers Prev. 2021-2
Int J Mol Sci. 2020-11-20
Curr Genomics. 2020-9
Int J Popul Data Sci. 2018-7-10
J Gerontol A Biol Sci Med Sci. 2020-11-13